ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

July 13, 2007

How Cancer Control Grants, Contracts Distributed By States

October 13, 1978

Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer

June 28, 2013

Review Of NTP Could Lead To Administrative Changes

April 18, 1980

Response From Center Representatives In L.A. To NCI Questions Is “Frusterating,” DeVita Says

April 13, 1984

Nexavar Approved For Patients With Inoperable Liver Cancer

November 30, 2007